- More than 90,000,000 diagnosed prevalent cases of AIS are anticipated in 2023 in the 16 countries covered in the publisher's epidemiology forecast for AIS.
 - There are only eight marketed drugs for AIS, with alteplase being marketed by various companies under various brand names and in multiple geographies.
 - The pipeline for AIS is very robust with one drug in pre-registration stage, whereas 13 drugs are currently in Phase III development stage.
 - Over the past 10 years, a total of 662 trials have been conducted for AIS. The highest number of trials occurred in 2021, with 100 trials, followed by 2022 with 92 trials.
 - In the development of AIS assets, licensing agreements emerged as the dominant deal type in South America and Africa. Acquisitions and partnership displayed prevalence in the markets of Europe, Asia-Pacific, and North America.
 
Scope
The publisher's AIS: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include -
- Disease Landscape
 - Disease Overview
 - Epidemiology Overview
 - Treatment Overview
 - Marketed Products Assessment
 - Breakdown by Mechanism of Action, Route of Administration
 - Product Profiles with Sales Forecast
 - Pricing and Reimbursement Assessment
 - Annual Therapy Cost
 - Time to Pricing and Time to Reimbursement
 - Pipeline Assessment
 - Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
 - Product Profiles with Sales Forecast
 - Late-to-mid-stage Pipeline Drugs
 - Phase Transition Success Rate and Likelihood of Approval
 - Clinical Trials Assessment
 - Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
 - Enrolment Analytics, Site Analytics, Feasibility Analysis
 - Deals Landscape
 - Mergers, Acquisitions, and Strategic Alliances by Region
 - Overview of Recent Deals
 - Commercial Assessment
 - Key Market Players
 - Future Market Catalysts
 
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
 - Develop business strategies by understanding the trends shaping and driving the AIS market.
 - Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AIS market in the future.
 - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
 - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
 - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
 

